CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
By newsfeedback@fool.com (Sara Appino)
Read original article on Motley FoolChoosing between the cutting-edge potential of CRISPR Therapeutics (NASDAQ:CRSP) and the established commercial success of Vertex Pharmaceuticals (NASDAQ:VRTX) is a classic debate for biotech investors. Both companies are currently shaping the future of medicine through gene-based therapies.
CRISPR Therapeutics is a younger, research-focused pioneer that recently achieved its first product approval. Vertex is a cash-generating giant that provides the commercial muscle and funding for their shared lead program. Comparing these two reveals very different approaches to the high-stakes world of modern medicine.
CRISPR Therapeutics focuses on developing transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. Its primary business strategy involves collaborating with larger partners to bring complex treatments like CASGEVY to patients with sickle cell disease and transfusion-dependent beta thalassemia. This helps the company manage the high costs of biotech stocks that are moving from research to commercialization.
This story was originally published on Motley Fool. DennTech aggregates headlines from top crypto publications to keep traders informed.
Read full article on Motley Fool